LP
VKTX icon

LMR Partners’s Viking Therapeutics VKTX Stock Holding History

LMR Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$158K – 1649
2024
Q4 		$201K Buy
+5,000
New +$285K ﹤0.01% 951
2023
Q2 		– Sell
-22,299
Closed -$371K – 1129
2023
Q1 		$371K Sell
22,299
-9,533
-30% -$98.5K 0.01% 765
2022
Q4 		$299K Buy
31,832
+7,432
+30% +$33.2K 0.01% 953
2022
Q3 		$66K Hold
24,400
– – ﹤0.01% 1075
2022
Q2 		$71K Buy
+24,400
New +$60.4K ﹤0.01% 1127
2018
Q4 		– Sell
-12,316
Closed -$215K – 486
2018
Q3 		$215K Buy
+12,316
New +$147K 0.01% 294

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LMR Partners's VKTX Position: Q1 2025 in Review

LMR Partners sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 5,000 shares — an estimated $158K sold.

LMR Partners first reported a position in VKTX in Q3 2018 and held it in 6 quarters. The position peaked at $371K in Q1 2023. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • LMR Partners reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 5,000 Viking Therapeutics shares in Q1 2025, an estimated $158K.
  • LMR Partners first reported a position in Viking Therapeutics in Q3 2018 and held it in 6 quarters.
  • LMR Partners's Viking Therapeutics position peaked at $371K in Q1 2023.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.